The positive Phase 1 data and regulatory designations de-risk PCRX-201 to some extent, but the next major catalyst is the Phase 2 ASCEND topline readout expected year-end 2026. Investors should monitor enrollment updates and any interim data releases. The stock may see a modest positive reaction on this clinical milestone, but prolonged duration of effect (measured in years) would be a key differentiator from current therapies lasting 3-6 months.
PCRX drugs
PCRX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 6 $25.58entry
- T+1 · 3mo ago −2.19%α −2.80% · $25.02
- T+5 · 3mo ago −9.38%α −10.60% · $23.18
- T+20 · 3mo ago +3.99%α +3.39% · $26.60
- T+60 · 18d ago +42.26%α +43.93% · $36.39
Price Chart
How similar events traded
Executive Summary
Pacira BioSciences reported positive two-year Phase 1 data for PCRX-201, a gene therapy for knee osteoarthritis, published in Annals of the Rheumatic Diseases. The single intra-articular injection was well tolerated and exploratory outcomes showed sustained improvements in pain, stiffness, and function across all doses. The Phase 2 ASCEND trial is ongoing with first topline readout expected by year-end 2026, and PCRX-201 has RMAT and ATMP regulatory designations.
Key Facts
- Phase 1 data for PCRX-201 shows safety and exploratory efficacy through two years in moderate-to-severe knee OA
- Results published in Annals of the Rheumatic Diseases, a top-tier rheumatology journal
- Phase 2 ASCEND trial (Part B) enrollment initiated, with scalable manufacturing transitioned
- PCRX-201 has received RMAT designation from FDA and ATMP designation from EMA
- First topline Phase 2 data expected year-end 2026
Financial Impact
No near-term revenue impact; potential depends on Phase 2/3 success. Knee OA affects >15M US patients, representing a multi-billion-dollar market opportunity if PCRX-201 is approved.
Risk Factors
- Phase 2 ASCEND trial may fail to replicate Phase 1 findings
- Manufacturing scale-up and cost of goods for gene therapy remain unproven at commercial scale
- Competition from other non-opioid pain therapies and existing OA treatments
- Regulatory hurdles for a novel gene therapy in a non-life-threatening condition
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3340186 |
Track record
29 reports on PCRX
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +6.07% at T+60 after the Apr 13, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $36.46 Now $36.48 −0.05% settles Dec 14
- Nov 12, 20264d ago SC TO-T/A Mixed 7/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 12, 20264d ago SC 14D-9/A Neutral 3/10 Entry $36.46 Now $36.48 +0.05% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $36.43 Now $36.48 +0.14% settles Dec 7
- Nov 3, 202613d ago SC 14D-9/A Neutral 3/10 Entry $36.40 Now $36.48 +0.22% settles Dec 3
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC 14D-9 Bullish 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 30, 202617d ago SC TO-T Mixed 7/10 Entry $36.39 Now $36.48 +0.25% settles Nov 30
- Oct 13, 20264w ago SC 13D/A Bearish 7/10 Entry $36.40 to $36.46 Now $36.48 −0.22% ▼ −0.16% −1.44% vs SPY
- Oct 8, 20265w ago SC TO-C Bullish 7/10 Entry $36.31 to $36.43 Now $36.48 +0.47% ▲ +0.33% +5.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers